Up to 10% of the population has difficulty maintaining muscle mass due to variant genes. SNP Therapeutics has developed a genetic test and algorithm that can identify a subset of the population who are unable to maintain muscle mass due to SNPs preventing the proper metabolism of one carbon nutrients.
Muscle Wasting Market Opportunity
Thirty two million americans suffer with muscle wasting. The market is forecast to grow to nearly $4Bn by 2024.
SNP Therapeutics is well positioned to participate in this growing market with potential products focusing in the Sports Nutrition and Aging Consumer Health segments.
SNP Therapeutics is seeking partnerships to develop clinical studies focused on identifying and treating athletes, the elderly, as well as military patient populations.